CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

quinapril

Trade name: accupril

Small moleculeapproved

Approved

Nov 19, 1991

Quinapril is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. Quinapril is indicated for the treatment of high blood pressure (hypertension) and as adjunctive therapy in the management of heart failure. It may be used for the treatment of hypertension by itself or in combination with thiazide diuretics, and with diuretics and digoxin for heart failure. — NCATS

Clinical trial activity

31 trials · 48 clinical orgs · 14 marketing orgs

Phase 1
10
Phase 2
1
Phase 3
1
Phase 4
16

Earliest trial started Jan 1, 1999 (NCT03031834)

Timeline

1990s

  1. Nov 19, 1991

    Pfizer — Earliest FDA Approval

  2. Nov 19, 1991

    Pfizer — NDA Secondary Org

  3. Nov 19, 1991

    Pfizer — NDA Organization

2000s

  1. Jan 1, 2002

    Mylan — Earliest Phase 1 Sponsor(trial)

  2. May 24, 2002

    Mylan — Marketing Organization

  3. Mar 31, 2004

    Lupin — Marketing Organization

  4. Dec 15, 2004

    Sun Pharmaceuticals — Marketing Organization

  5. Dec 22, 2004

    Actavis — Marketing Organization

  6. Dec 23, 2004

    PHARMOBEDIENT — Marketing Organization

  7. Mar 2, 2005

    Chartwell Pharmaceuticals — Marketing Organization

  8. Mar 2, 2005

    Fosun — Marketing Organization

  9. Jan 26, 2006

    Apotex — Marketing Organization

  10. Aug 24, 2007

    Invagen Pharms — Marketing Organization

  11. Aug 24, 2007

    Teva — Marketing Organization

  12. Aug 24, 2007

    Ani Pharmaceuticals — Marketing Organization

  13. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Apr 29, 2013

    Aurobindo Pharma — Marketing Organization

  2. Sep 15, 2016

    Prinston Inc — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedNov 19, 1991

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
Mol. weight
438.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warningProdrug

Sources

Also known as

  • 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
  • 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, monohydrochloride, (3s-(2(r*(r*)),3r*))-
  • accupril
  • accupril
  • accupril
  • accupril
  • accupril
  • accupro
  • accupro
  • ci 906
  • ci-906
  • ci-906
  • ci-906
  • ectren
  • koretic
  • pd 109452-2
  • pd-109,452-2
  • qualaquin
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinapril
  • quinaprilat
  • quinapril hcl
  • quinapril hcl
  • quinapril hcl
  • quinapril hydrochloride
  • quinapril hydrochloride
  • quinapril hydrochloride
  • quinapril hydrochloride
  • quinapril hydrochloride
  • quinaprilum
  • quinaprilum
  • quinil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07027982Phase 1Jul 16, 2025Dong-A Pharmaceutical
NCT02981212Phase 4Jun 1, 2016Catholic University of Korea, Chonbuk National University, Chong Kun Dang Pharmaceutical, Inje University, Kyung Hee University, Kyungpook University, Pusan National University, Yonsei University
NCT02817360Phase 4Feb 1, 2016Medical University of Vienna, University of Vienna
NCT01669434Phase 4Jun 1, 2015University of Nebraska
NCT01889420Phase 1Jul 1, 2014New Mexico Cancer Care Alliance, Novartis, University of New Mexico
NCT01352689Phase 1Apr 1, 2011Chong Kun Dang Pharmaceutical
NCT01301599Phase 4Jan 1, 2011Sungkyunkwan University
NCT01340131Phase 1Jan 1, 2011Chong Kun Dang Pharmaceutical, Inje University
NCT01246193Phase 1Nov 1, 2010Chong Kun Dang Pharmaceutical, Inje University
NCT00438113Phase 4Dec 1, 2009Dalhousie University, Government of Canada, Nova Scotia Health Research Foundation
NCT01581476Phase 3Jan 1, 2009British Heart Foundation, Diabetes UK, Juvenile Diabetes Research Foundation, Pfizer, University of Cambridge, University of London, University of Oxford, University of Toronto, University of Western Australia
NCT00741585Phase 4Sep 1, 2008University of Vigo
NCT00795262N/AJul 1, 2008Atlanta Vascular Research Foundation, InVasc Therapeutics, Inc.
NCT00872781N/AOct 1, 2007Ranbaxy
NCT00785486Phase 1Mar 1, 2007MDS Pharma, Mutual Pharmaceutical
NCT00313547Phase 4Apr 1, 2006Pfizer, University of Montreal
NCT00872235N/AJun 1, 2005Ranbaxy
NCT00353652Phase 4Jan 1, 2005National Heart, Lung, and Blood Institute (NHLBI), The University of Texas, Dallas
NCT00154050N/AMay 1, 2004Technical University of Dresden
NCT00299221Phase 4Apr 1, 2004Astellas, Newark Beth Israel Medical Center
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (48)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit5221999
Chong Kun Dang PharmaceuticalFor profit4322010
MylanFor profit4412002
PRACSFor profit4012002
Inje UniversityAcademic/Hospital3022010
National Heart, Lung, and Blood Institute (NHLBI)Government2012000
RanbaxyFor profit2212005
University of MontrealAcademic/Hospital2211999
University of TorontoAcademic/Hospital2122002
University of VigoAcademic/Hospital2212000
Aristotle University of ThessalonikiAcademic/Hospital1111999
AstellasFor profit1012004
Atlanta Vascular Research FoundationAcademic/Hospital1012008
British Heart FoundationAcademic/Hospital1012009
Catholic University of KoreaAcademic/Hospital1012016
Chonbuk National UniversityAcademic/Hospital1012016
Dalhousie UniversityAcademic/Hospital1012009
Diabetes UKAcademic/Hospital1012009
Dong-A PharmaceuticalFor profit1112025
Government of CanadaGovernment1112009
48 organizations
Page 1 / 3

Marketing (20)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGDec 22, 2004
ActavisFor profitSYNJan 14, 2005
Ani PharmaceuticalsFor profitMKTGAug 24, 2007
Ani PharmaceuticalsFor profitSYNAug 24, 2007
ApotexFor profitSYNMar 12, 2013
ApotexFor profitMKTGJan 26, 2006
ApotexFor profitSYNMar 12, 2013
Aurobindo PharmaFor profitSYNAug 24, 2007
Aurobindo PharmaFor profitMKTGApr 29, 2013
Chartwell PharmaceuticalsFor profitMKTGMar 2, 2005
FosunFor profitMKTGMar 2, 2005
Invagen PharmsFor profitMKTGAug 24, 2007
LupinFor profitMKTGMar 31, 2004
MylanFor profitMKTGMay 24, 2002
PHARMOBEDIENTFor profitMKTGDec 23, 2004
PfizerFor profitNDA2Nov 19, 1991
PfizerFor profitNDANov 19, 1991
Prinston IncFor profitMKTGSep 15, 2016
Sun PharmaceuticalsFor profitMKTGDec 15, 2004
TevaFor profitMKTGAug 24, 2007